X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Akynzeo is a combination of netupitant, a selective antagonist of human substance P/neurokinin 1 (NK-1) receptors and palonosetron, a 5-HT3 receptor antagonist with a strong binding affinity for this receptor. It is indicated for nausea due to cancer chemotherapy.
Lead Product(s): Netupitant,Palonosetron
Therapeutic Area: Gastroenterology Product Name: Akynzeo
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 03, 2023
Details:
Akynzeo (netupitant) is a 5-HT3 and NK1 receptor antagonist fixed combination approved in Europe in adults for the prevention of acute and delayed nausea and vomiting associated with cisplatin-based highly emetogenic chemotherapy and moderately emetogenic chemotherapy.
Lead Product(s): Netupitant,Palonosetron
Therapeutic Area: Gastroenterology Product Name: Akynzeo
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Immedica Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 24, 2023
Details:
Adlumiz (anamorelin) is a selective, novel, orally active ghrelin receptor agonist. Upon binding to its receptor, ghrelin stimulates multiple pathways in the positive regulation of body weight, muscle mass, appetite and metabolism.
Lead Product(s): Anamorelin
Therapeutic Area: Nutrition and Weight Loss Product Name: Adlumiz
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Oberland Capital Management
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing January 10, 2023
Details:
AKYNZEO (Netupitant) is the first and only 5-HT3 and NK1 receptor antagonist fixed combination approved in adults for the prevention of acute and delayed nausea and vomiting associated with cisplatin based highly emetogenic chemotherapy and moderately emetogenic chemotherapy.
Lead Product(s): Netupitant,Palonosetron
Therapeutic Area: Gastroenterology Product Name: Akynzeo
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 04, 2023
Details:
Akynzeo is the first and only 5-HT3 and NK1 receptor antagonist fixed combination approved in adults for the prevention of acute and delayed nausea and vomiting associated with highly and moderately emetogenic chemotherapy.
Lead Product(s): Netupitant,Palonosetron
Therapeutic Area: Gastroenterology Product Name: Akynzeo
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 29, 2022
Details:
VALCHLOR® (mechlorethamine) gel 0.016% is indicated for the topical treatment of Stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL) in patients who have received prior skin-directed therapy.
Lead Product(s): Mechlorethamine
Therapeutic Area: Oncology Product Name: Ledaga
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 18, 2022
Details:
LEDAGA® (chlormethine) gel is an alkylating drug indicated for the topical treatment of MF-CTCL in adult patients. LEDAGA® is a gel which is applied topically once a day.
Lead Product(s): Mechlorethamine
Therapeutic Area: Oncology Product Name: Ledaga
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 21, 2022
Details:
Under the agreement, the registeration, distribution, promotion, market and sell LEDAGA® (chlormethine gel) in Australia, Asia and the Middle East* as a topical treatment of mycosis fungoides-type cutaneous T-cell lymphoma (“MF-CTCL”) in adults.
Lead Product(s): Mechlorethamine
Therapeutic Area: Oncology Product Name: Ledaga
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Juniper Biologics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement September 01, 2022
Details:
Vepafestinib (also known as TAS0953/HM06 is an investigational, potent, orally administered, and highly selective RET inhibitor1,4. In preclinical studies, vepafestinib has shown activity against RET solvent front (G810) and gatekeeper (V804) mutations.
Lead Product(s): Vepafestinib
Therapeutic Area: Oncology Product Name: TAS0953
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 08, 2022
Details:
Vepafestinib (TAS0953/HM06) is an investigational, potent, orally administered, highly selective RET inhibitor, is pharmacologically distinct, exhibits a distinct binding mode to RET, and has shown evidence of enhanced brain penetrability characteristics in preclinical model.
Lead Product(s): Vepafestinib
Therapeutic Area: Oncology Product Name: TAS0953
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Taiho Pharmaceutical
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 02, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
